Due to the success of current treatments, patients are living longer and surviving cancer. However, certain treatments can cause cardiac complications which have a significant impact on the individual’s health. Cancer patients, with either preexisting cardiac disease or increased cardiac risk, require individualized risk stratification strategies when planning their treatment. In this interview, Alex Lyon, MA, BM BCh, PhD, FRCP, from Imperial College, London, UK, discusses the need for more trials looking into systems of care to be carried out, rather than just those investigating specific pharmacological interventions. Preclinical identification of cardiac toxicities and personalized treatment help improve patient outcomes for those at high-risk of cardiac complications. This interview was recorded at the British Society for Hematology (BSH) 2018 Annual Scientific Meeting, Liverpool, UK.